Sophia Randolph
- Oncology top 0.5%
- Pulmonary and Respiratory Medicine top 0.2%
- Cancer Research top 1%
- Molecular Biology top 5%
- Genetics top 0.5%
- Co-authors
- Richard S. FinnDennis J. SlamonNadia HarbeckKaren A. GelmonSeock‐Ah ImHope S. RugoEric GauthierMiguel Martín
- Topics
- Advanced Breast Cancer Therapies (33 papers)HER2/EGFR in Cancer Research (16 papers)Phagocytosis and Immune Regulation (14 papers)
- Journals
- New England Journal of MedicineJournal of Clinical OncologySHILAP Revista de lepidopterología
- Partner nations
- United StatesSouth KoreaGermany
In The Last Decade
Sophia Randolph
66 papers receiving 6.7k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Oncology 4.7k
- Pulmonary and Respiratory Medicine 4.6k
- Cancer Research 1.6k
- Molecular Biology 1.6k
- Genetics 1.2k
Countries citing papers authored by Sophia Randolph
This map shows the geographic impact of Sophia Randolph's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sophia Randolph with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sophia Randolph more than expected).
Fields of papers citing papers by Sophia Randolph
This network shows the impact of papers produced by Sophia Randolph. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sophia Randolph. The network helps show where Sophia Randolph may publish in the future.
Co-authorship network of co-authors of Sophia Randolph
This figure shows the co-authorship network connecting the top 25 collaborators of Sophia Randolph. A scholar is included among the top collaborators of Sophia Randolph based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sophia Randolph. Sophia Randolph is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 1 | |
| 3 | 10 | |
| 4 | 23 | |
| 5 | 8 | |
| 6 | 136 | |
| 7 | Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancerbreakdown → | 1111 |
| 8 | 1 | |
| 9 | The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studybreakdown → | 1412 |
| 10 | 154 | |
| 11 | 5 | |
| 12 | 86 | |
| 13 | 30 | |
| 14 | 295 | |
| 15 | 4 | |
| 16 | 158 | |
| 17 | 138 | |
| 18 | 139 | |
| 19 | 7 | |
| 20 | 57 |
About Sophia Randolph
Sophia Randolph is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine, having authored 69 papers that have together received 6.8k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (33 papers), HER2/EGFR in Cancer Research (16 papers) and Phagocytosis and Immune Regulation (14 papers). The work is most often cited by research in Oncology (4.7k citations), Pulmonary and Respiratory Medicine (4.6k citations) and Genetics (1.2k citations). Sophia Randolph has collaborated with scholars based in United States, South Korea and Germany. Frequent co-authors include Richard S. Finn, Dennis J. Slamon, Nadia Harbeck, Karen A. Gelmon, Seock‐Ah Im, Hope S. Rugo, Eric Gauthier, Miguel Martín, Stephen E. Jones and Véronique Dièras. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.